USA -QIAGEN and Bio-Rad Laboratories Inc. are negotiating about combining the two companies, The Wall Street Journal has reported.
Unnamed sources briefed on the talks said the worth of a potential agreement between two life science research companies could surpass US$10 billion.
While negotiations have been ongoing for some time, an agreement is unlikely to be reached for several weeks, and the deal may still fall through, according to the report.
Bio-Rad, based in Hercules, California, manufactures a variety of products for the life science research and clinical diagnostic markets.
It has a market capitalization of slightly less than US$12 billion. Qiagen is a diagnostics company based in Germany with a market capitalization of around US$10 billion.
In 2020, Thermo Fisher attempted to acquire Qiagen in a deal valued at US$11.5 billion. That deal fell apart after Qiagen’s shareholders refused to support it.
Last year, Thermo Fisher paid US$17.4 billion for research contractor PPD.
The report of a Bio-Rad tie-up with Qiagen comes amid a lull of medtech mergers and acquisitions following a spending spree last year.
Notable acquisitions this year include Stryker’s US$3 billion purchase of Vocera Communications, ResMed’s approximately US$1 billion pickup of MediFox Dan, and Becton Dickinson’s US$1.53 billion purchase of Parata Systems.
According to the McKinsey M&A Practice review of the global M&A market, 2022 activity has declined, but only slightly.
Deal makers in the Americas have been the most active traders, delivering almost half of worldwide deal value (48 percent, versus 52 percent for all of 2021).
Europe, the Middle East, and Africa’s share is up slightly (28 percent, versus 26 percent), as is Asia–Pacific’s share (24 percent, versus 22 percent).
Cross-border M&A deals totaled US$2.7bn globally
According to an analysis report by Medical Devices Network, the medical devices industry cross-border M&A deals totaled US$2.7bn globally in Q2 2022.
The top five cross-border M&A deals in medical devices industry accounted for 54.5 percent of the overall value during Q2 2022.
The combined value of the top deals stood at US$2.09bn, against the overall value of US$2.7bn recorded for the quarter.
The analysis ranks the top five Medical devices industry cross-border Medical devices deals of Q2 2022 tracked by GlobalData as follows:
1) ResMed US$1bn acquisition deal with MediFox DAN Group
2) The US$541.63m acquisition of Phenox by Wallaby Medical
3) Boston Scientific US$230m acquisition deal for 64 percent stake in M.I.Tech
4) The US$177.8m acquisition of Guardant Health AMEA by Guardant Health
5) Integer US$141.73m acquisition deal with Aran Biomedical
Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE
